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Objectives: Widespread use of b-lactam antibiotics could cause resistance to this
group of antibiotics in pathogenic bacteria through the production of the enzyme b-
lactamases. The aimof this study is to determine themolecular detection of AmpC b-
lactamases among clinical Escherichia coli isolated from Ilam hospitals in Ilam, Iran.
Methods: One hundred and twelve clinical isolates of E. coli were collected from
hospitalized patients and were identified by biochemical tests. They were evalu-
ated for extended spectrum beta-lactamases (ESBLs) production, and the positive
strains were subjected to AmpC enzymes; for detection of AmpC cluster genes,
multiplex polymerase chain reaction was applied.
Results: The analysis showed 62.5% of isolates were ESBLs positive and that five
strains revealed the AmpC cluster genes. This is the first report of FOXM cluster
genes in E. coli in Iran.
Conclusion: Based on our results, the prevalence of AmpC b-lactamases is
increasing in Iran, which caused failure in antibiotic therapy. So, the current study
recommended the revision of antibiotic policy in Iranian hospitals.1. Introduction
Production of b-lactamases are the main mechanism
of resistance to b-lactam antibiotics in bacteria. These
enzymes hydrolyze the b-lactam ring, which leads to
the inactivation of b-lactam antibiotics. In recent years,
new types of b-lactamase enzymes including
extended spectrum beta-lactamases (ESBLs), AmpCted under the terms of the C
0) which permits unrestrict
roperly cited.
ase Control and Preventionb-lactamases, and metallo b-lactamases have emerged.
[1e3]. These enzymes are able to hydrolyze broad-
spectrum cephalosporins including ceftazidime, ceftri-
axone, cefepime, and monobactams (aztreonam and
cephamycin). AmpC b-lactamases are resistant to 7-
alfa methoxy cephalosporin and monobactams. In the
late 1980s, the plasmid-borne AmpC b-lactamases
were found in bacteria such as Escherichia coli andreative Commons Attribution Non-Commercial License (http://
ed non-commercial use, distribution, and reproduction in any
. Published by Elsevier Korea LLC. All rights reserved.
202 A. Maleki, et alKlebsiella spp [4,5]. Currently, resistance to b-lactam
antibiotics via AmpC b-lactamases in E. coli strains is
a clinical concern [6,7]. It seems necessary to identify
the AmpC b-lactamases producing bacteria in clinical
isolates. For this propose we aim to identify the prev-
alence of AmpC b-lactamases genes in clinical isolates
of E. coli.Figure 1. 1 and 8Z negative control; 2ZFOXM(190 bp) and
DHAM (405 bp); 3 Z EBCM (302 bp) and DHAM (405 bp);
4Z EBCM (302 bp) and FOXM (190 bp); 5Z CITM (462 bp);
M Z size marker 100 bp; 6 Z FOXM (190 bp); 7 Z FOXM
(190bp), EBCM (302 bp) and CITM (462 bp).2. Materials and methods
2.1. Bacterial isolates
One hundred and twelve clinical isolates of E. coli
were collected during the period February to July 2012
from hospitalized patients in Ilam hospitals (Ilam, Iran).
All the isolates were identified by biochemical tests.
2.2. Determination of antibiotic susceptibility
The antibiotic susceptibility assay was performed
according to Clinical and Laboratory Standards Institute
(CLSI) guidelines. An inoculum containing
1.5  108 CFU/mL of bacteria were placed on Mueller-
Hinton agar. The antibiotics were cefotaxime (30 mg),
ceftazidime (30 mg), and cefteriaxone (30 mg). In addi-
tion, cefoxitin as a marker for AmpC production was
used. AmpC b-lactamase production was evaluated by
cefoxitin minimum inhibitory concentrations (MICs)
using the microdilution broth method according to CLSI
guidelines [8].
2.3. DNA extraction
E. coli strains were cultured in lysogeny broth at
37C overnight, and then DNA was extracted using the
DNA extraction kit (Bionner Company, Daejeon,
Korea).
2.4. Multiplex polymerase chain reaction assay
Multiplex polymerase chain reaction (PCR) assay
was performed for identification of the most common
plasmid mediated AmpC cluster genes including ACC,Table 1. Sequences of primers.
Primer Sequence (50 to 30)
MOXM-F
MOXM-R
GCT GCT CAA GGA GCA CAG GAT
CAC ATT GAC ATA GGT GTG GTG G
CITM-F
CITM-R
TGG CCA GAA CTG ACA GGC AAA
TTT CTC CTG AAC GTG GCT GGC
DHAM-F
DHAM-R
AAC TTT CAC AGG TGT GCT GGG T
CCG TAC GCA TAC TGG CTT TGC
ACCM-F
ACCM-R
AAC AGC CTC AGC AGC CGG TTA
TTC GCC GCA ATC ATC CCT AGC
EBCM-F
EBCM-R
TCG GTA AAG CCG ATG TTG CGG
CTT CCA CTG CGG CTG CCA GTT
FOXM-F
FOXM-R
AAC ATG GGG TAT CAG GGA GAT G
CAA AGC GCG TAA CCG GAT TGGFOX, MOX, DHA, CIT, and EBC. The PCR system
(25 mL) was composed of 1 PCR buffer, 2 mM MgCl2,
0.2 mM dNTP, 10 pmol of primers, 1U Taq DNA po-
lymerase (Ferments, UK), and a total of 1 mL of DNA
extract was used for each reaction. The sequences of
primers are presented in Table 1. PCR conditions were
35 cycles of amplification under the following condi-
tions: denaturation at 95C for 30 seconds, annealing at
64C for 1 minute, and extension at 72C for 1 minute.
Cycling was followed by a final extension at 72C for
10 minutes. PCR product (10 mL) was analyzed using
gel electrophoresis with 1.5% agarose. Gels were
stained with DNA Safe Stain and visualized using gel
documentation. A 100-bp DNA ladder was used as a
molecular marker.Expected amplicon size (bp) Annealing
520 64
462 64
405 64
346 64
302 64
190 64
Figure 2. Prevalence of different AmpC cluster genes in ESBL positive E. coli strains.
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3.1. ESBLs were presented in large scale of
isolates
The analysis revealed 62.5% of isolates (n Z 70)
were ESBLs positive and that antibiotic susceptibility
was resistant to ceftazidime, cefotaxime, and cefteriax-
one. MICs microdilution broth test for identification of
cefoxitin resistance isolates showed that among the 70
ESBL-positive strains, 40% (n Z 28) of isolates
exhibited resistance to cefoxitin (MIC  32 mg/L).
3.2. Multiplex PCR showed AmpC cluster genes
in ESBL-positive strains
The multiplex PCR results of 70 ESBL-positive
strains revealed that two isolates (85%) were positive
for CITM cluster gene, two isolates (85%) were positive
for DHAM cluster gene, three isolates (28%) were pos-
itive for EBCM cluster gene, and three isolates (28%)
were positive for FOXM cluster gene. One strain pre-
sented CITM, EBCM, and FOXM cluster genes simul-
taneously. One strain had FOXM and EBCM cluster
genes, one strain showed DHAM and EBCM cluster
genes, and finally, in one strain FOXM and DHAM
cluster genes were observed (Figures 1 and 2). ACCM
and MOXM cluster genes were not found in this study.4. Discussion
b-Lactamases are the main defensive system against
b-lactam antibiotics. As long as b-lactam antibiotics
have been used in clinical treatment, b-lactamases havehad a main role in treatment failure. Approximately
30 years ago, researchers identified the plasmids
responsible for antibiotics resistance genes in E. coli and
other Enterobacteriaceae [9]. The chromosomal AmpC
was found in a small scale in E. coli, whereas most
strains showed the AmpC enzyme in plasmids in E. coli
[4]. In this study, among 112 isolates of E. coli, 70
isolates indicated as ESBL positive phenotypically
showed that 28 of them had the AmpC phenotype. These
28 isolates were resistant to cefoxitin (MIC  32 mg/L).
According to the PCR assay results, we found four types
of cluster genes in five isolates (14%) indicating the
prevalence of AmpC b-lactamases in Iran. Many
important factors, such as the indiscriminate use and
availability of antibiotics and their ease of preparation
from pharmacies, could be noted. The study by Man-
souri et al [10] indicated that among 88 clinical isolates
of E. coli, five (7%) had AmpC genes that belong to
DHAM, CITM, and EBCM cluster genes. Japoni-Nejad
et al [11] showed that in Iran among 100 isolates of
Klebsiella pneumonia, 19 isolates had AmpC genes that
belong to DHAM, CITM, EBCM, and MOXM cluster
genes. The study by Dallai et al [12] showed that among
128 clinical isolates, five were positive for DHA cluster
gene. According to our investigations in this study we
reported the first case of FOXM cluster gene in E. coli in
Iran. Based on the aforementioned studies, the preva-
lence of AmpC b-lactamases is increasing in Iran.Conflicts of interest
The authors declare no conflicts of interest.
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